Piramal Pharma Limited (PPLPHARMA)
Press Release
Press Release - Q2FY27
- Revenue 2,617 Cr +28% y-y; EBITDA 385 Cr +72% y-y; EBITDA margin 14.7% (11.0%); PAT 5 Cr vs loss of 99 Cr
- FY27 revenue growth outlook upgraded to 19-20% with higher profitability
- CDMO business grew 36% in Q2, driven by strong order inflows and capacity utilization
- CHG business grew 32%, led by US inhalation anesthesia leadership and Kenalog integration
- Consumer Healthcare grew 13%, powered by Power Brands and 32% e-commerce growth
- Successfully completed 12 regulatory inspections and 110 customer audits in H1FY27
- Net debt increased to 4,859 Cr; total equity stable at 8,165 Cr
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 PPLPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add PPLPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Piramal Pharma Limited
Important.
The summary above is generated automatically from Piramal Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.